GH earnings analysis
What we found in GH's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Guardant Health reported a strong Q1 2026 with revenue of $301.7 million, significantly surpassing prior estimates and reflecting a 48% year-over-year increase. However, the company also faced a net loss of $112.1 million, up from $95.2 million a year earlier, indicating ongoing challenges despite revenue growth. Management raised full-year revenue guidance to between $1.30 billion and $1.32 billion, reflecting optimism in its oncology and screening segments.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Revenue Beats Expectations
- Q1 2026 revenue reached $301.7 million, beating the estimate of $278.9 million by 8.1%.
- Oncology Revenue Growth
- Oncology revenue increased by $54.4 million, or 36%, totaling $205.0 million for Q1 2026.
- Massive Increase in Screening Revenue
- Screening revenue surged to $41.6 million from just $5.7 million a year ago, marking a 633% increase.
- EPS Surprised to the Upside
- Q1 2026 EPS was reported at -$0.45, beating the estimated -$0.52 by 13.5%.
- Cash Position Strong
- As of March 31, 2026, the company had approximately $1.2 billion in cash, cash equivalents, and marketable securities.
- Guidance Raised
- Management raised 2026 revenue guidance to $1.30 to $1.32 billion from previous guidance of $1.25 to $1.28 billion.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Operating Losses Persist
- Net loss increased to $112.1 million in Q1 2026 compared to $95.2 million in Q1 2025.
- Rising Operating Expenses
- Total costs and expenses grew to $423.0 million, up from $314.5 million year-over-year.
- Dependence on Reimbursement Rates
- Revenue and margins heavily affected by payer reimbursement decisions and coverage, creating variability.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-0.45
- Segment
- Oncology: $205M
- Segment
- Biopharma and Data: $53M
- Segment
- Screening: $41M
- Segment
- Licensing: $2.1M
What they said about what is next.
Revenue guidance raised, specifically to a range of $1.30 to $1.32 billion for 2026.
The filing reads better than the one before it.
What came before.
- 10-K · February 19, 2026
- Guardant Health positions itself as a precision oncology leader with a multi‑modal Smart Platform powering diagnostics across screening (Shield), MRD/monitoring (Reveal) and therapy selection (Guardant360/CDx), and…
- 10-K · February 20, 2025
- Guardant Health highlights product and regulatory progress (Shield FDA approval in July 2024 and Medicare coverage) and continued commercial expansion of its liquid biopsy portfolio (Guardant360 CDx and Guardant360…
- 10-Q · May 9, 2024
- Guardant Health reported Q1 revenue of $168,491,000, up from $128,714,000 a year ago (+$39,777,000; +30.9%), driven by precision oncology testing. Gross margin remained healthy at ~61.3% while the company continued to…
- 10-K · February 22, 2024
- Guardant Health positions itself as a leading precision-oncology company with a product strategy spanning therapy selection, monitoring (MRD), and early detection and a data platform (GuardantINFORM) to support…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing GH makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever